Premera Blue Cross updated the MDC 09 (Dermatology & Plastic Surgery — Skin/Breast) non‑covered/experimental coding list effective 2026‑03‑01, adding several new Category III and other codes for emerging dermatologic and breast procedures. Newly listed codes include adipose‑derived regenerative cell therapy for scleroderma of the hands (0489T, 0490T), molecular fluorescent nevus imaging (0700T, 0701T, e.g., Orlucent), and percutaneous breast tumor ablation (0970T, 0971T). The policy groups these with other novel imaging, quantitative MR, device and procedural codes (e.g., 0698T series) to clarify they are considered experimental/investigational and non‑covered under MDC 09. Providers should review these additions when submitting or authorizing services related to these technologies.
March 2026 Revision: New and Highlighted Codes in MDC 09
Summary of changes in this revision
This document lists coding entries added or emphasized in the Non-covered Experimental/Investigational Services policy for MDC 09: Dermatology & Plastic Surgery (Skin/Breast) under premera-bluecross, Policy 10.01.533_HMO, effective 2026-03-01. The updated coding section includes several new or specified CPT/HCPCS category II/III codes relevant to dermatology and breast procedures. Notable inclusions are codes for adipose-derived regenerative cell therapy for scleroderma of the hands (0489T, 0490T), molecular fluorescent nevus imaging (0700T, 0701T), and percutaneous breast tumor ablation (0970T, 0971T).
The coding blocks also show additional related technologies and procedures that are cataloged in this section (e.g., quantitative magnetic resonance codes 0698T, 0700T series, and other novel device/procedure codes effective 07/01/25). These entries indicate which specific services are being articulated within the non-covered/experimental investigational coding list for MDC 09.
Adipose‑derived Regenerative Cell Therapy for Scleroderma (`0489T`, `0490T`)
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.